Search
Xencor Inc
XNCRAdd to Watchlist
15.000USD
-0.380-2.47%
Close 07/02, 13:00（ET）Quotes delayed by 15 min
1.08BMarket Cap
LossP/E TTM
More Details of Xencor Inc Company
Xencor, Inc. is a clinical-stage biopharmaceutical company developing engineered antibodies for the treatment of cancer and autoimmune diseases. It has more than 20 candidates engineered with its XmAb technology that are in clinical development, and multiple XmAb medicines are marketed by partners. Its XmAb engineering technology enables small changes to a protein structure that result in new mechanisms of therapeutic action. Its wholly-owned development candidates include XmAb942, XmAb819, XmAb808, and XmAb541. Candidates co-developed with partners include Plamotamab. Its clinical-stage drug candidates advanced by partners include Xaluritamig (AMG 509), ASP2138, JNJ-9401, JNJ-1493, Xpro1595, Obexelimab, and Novartis XmAb, an undisclosed antibody candidate. Its cytokine drug candidates in clinical development consist of efbalropendekin alfa (XmAb306/RG6323). Its Vudalimab is a bispecific antibody that targets PD-1 and CTLA-4.
Xencor Inc Info
Ticker SymbolXNCR
Company nameXencor Inc
IPO dateDec 03, 2013
CEODahiyat (Bassil I)
Number of employees250
Security typeOrdinary Share
Fiscal year-endDec 03
Address465 N. Halstead St.
CityPASADENA
Stock exchangeNASDAQ OMX - NASDAQ BASIC
CountryUnited States of America
Postal code91107
Phone16263055900
Websitehttps://xencor.com/
Ticker SymbolXNCR
IPO dateDec 03, 2013
CEODahiyat (Bassil I)
Company Executives of Xencor Inc
Name
Name/Position
Position
Shareholding
Change
Dr. John R. Desjarlais, Ph.D.
Dr. John R. Desjarlais, Ph.D.
Executive Vice President - Research, Chief Scientific Officer
Executive Vice President - Research, Chief Scientific Officer
231.70K
+6.74%
Ms. Celia E. Eckert
Ms. Celia E. Eckert
Senior Vice President, General Counsel, Corporate Secretary
Senior Vice President, General Counsel, Corporate Secretary
57.51K
+21.17%
Mr. Bart Jan Cornelissen
Mr. Bart Jan Cornelissen
Senior Vice President, Chief Financial Officer
Senior Vice President, Chief Financial Officer
48.35K
-7.24%
Mr. Kurt A. Gustafson
Mr. Kurt A. Gustafson
Independent Director
Independent Director
1.02K
-535.09%
Mr. Richard J. (Rich) Ranieri
Mr. Richard J. (Rich) Ranieri
Independent Director
Independent Director
23.00
-23800.00%
Dr. Bassil I. Dahiyat, Ph.D.
Dr. Bassil I. Dahiyat, Ph.D.
President, Chief Executive Officer, Founder and Director
President, Chief Executive Officer, Founder and Director
--
--
Dr. A. Bruce Montgomery, M.D.
Dr. A. Bruce Montgomery, M.D.
Lead Independent Director
Lead Independent Director
--
--
Dr. Kevin C. Gorman, Ph.D.
Dr. Kevin C. Gorman, Ph.D.
Independent Director
Independent Director
--
--
Dr. Ellen Gwen Feigal, M.D.
Dr. Ellen Gwen Feigal, M.D.
Independent Director
Independent Director
--
--
Dr. Barbara J. Klencke, M.D.
Dr. Barbara J. Klencke, M.D.
Independent Director
Independent Director
--
--
View more
Name
Name/Position
Position
Shareholding
Change
Dr. John R. Desjarlais, Ph.D.
Dr. John R. Desjarlais, Ph.D.
Executive Vice President - Research, Chief Scientific Officer
Executive Vice President - Research, Chief Scientific Officer
231.70K
+6.74%
Ms. Celia E. Eckert
Ms. Celia E. Eckert
Senior Vice President, General Counsel, Corporate Secretary
Senior Vice President, General Counsel, Corporate Secretary
57.51K
+21.17%
Mr. Bart Jan Cornelissen
Mr. Bart Jan Cornelissen
Senior Vice President, Chief Financial Officer
Senior Vice President, Chief Financial Officer
48.35K
-7.24%
Mr. Kurt A. Gustafson
Mr. Kurt A. Gustafson
Independent Director
Independent Director
1.02K
-535.09%
Mr. Richard J. (Rich) Ranieri
Mr. Richard J. (Rich) Ranieri
Independent Director
Independent Director
23.00
-23800.00%
Dr. Bassil I. Dahiyat, Ph.D.
Dr. Bassil I. Dahiyat, Ph.D.
President, Chief Executive Officer, Founder and Director
President, Chief Executive Officer, Founder and Director
--
--
FAQs
Who are the top five shareholders of Xencor Inc?
The top five shareholders of Xencor Inc are: Dr. John R. Desjarlais, Ph.D.
What is the biggest source of revenue for Xencor Inc?
In 2026Q4, the Royalties business generated the highest revenue for Xencor Inc, amounting to 80.28M and accounting for 63.93% of total revenue.